Targets › PTPRZ1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2028.
Protein tyrosine phosphatase that negatively regulates oligodendrocyte precursor proliferation in the embryonic spinal cord. Required for normal differentiation of the precursor cells into mature, fully myelinating oligodendrocytes. (UniProt, P23471)
Open in Phaseline: the race on PTPRZ1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Cancer vaccine against TERT and PTPRZ1 Cancer vaccine targeting glioma-associated antigens (TERT and PTPRZ1) | TERT, PTPRZ1 | Phase 1 | Newly Diagnosed Glioblastoma | Mar 2028 |
Newly Diagnosed Glioblastoma (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.